focus -WSS

focus

author：hotspot 2025-10-02 21:00:40 - browse：73

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： ACIP vaccine advisory panel sees its vacancies filled

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Ebola vaccine can save some who are already sick, per new study

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

How to save health care price transparency rules

UCLA team creates talking throat patch for voice disorders

hotspot

focus

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

HHS secretary Becerra pressed on Change HealthCare cyberattack

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Change Healthcare outage fallout shows need for new oversight

Peter Hotez and the public health issue of online harassment

HHS secretary Becerra pressed on Change HealthCare cyberattack

Drug repurposing or repositioning? The language matters

Congress might make insulin pumps more accessible to the blind

Wildfire smoke exposes gaps in outdoor worker protections

Male and female sex labels in research insufficient, scientists say

leisure time

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Amid AI frenzy, a top HHS official's quest to create safeguards

As AI in medicine takes off, can 'human in the loop' prevent harm?

As AI in medicine takes off, can 'human in the loop' prevent harm?

HHS secretary Becerra pressed on Change HealthCare cyberattack

knowledge

focus

focus

hotspot